For liver cancer patients who cannot undergo surgery or develop distant metastasis, Sorafenib has good effect. Sorafenib is a kinase inhibitor, which can act on serine/threonine kinase and receptor tyrosine kinase on tumor cells and tumor blood vessels and inhibit their activities, thus inhibiting the proliferation of tumor cells. At present, the indications of Sorafenib in China are not only for inoperable advanced hepatocellular carcinoma, but also for advanced inoperable renal cell carcinoma and recurrent or metastatic differentiated thyroid cancer. It is important to note that sorafenib should not be used by pregnant or breastfeeding women to prevent serious effects on the development of the fetus or baby. Sorafenib can also impair a patient’s ability to reproduce. The most common adverse reactions to this medication are diarrhea, fatigue, hair loss, and infections. The use of Sorafenib in liver cancer patients should be under the supervision of an oncologist.